Patients with chronic myeloid leukemia (CML) are always worried when their WBC Count increases. At Asian Cancer Institute our expert Medical Oncologists and Hematologist understand very well which of such patients have a problem and which don’t. We know that significant number of patients treated with the tyrosine kinase inhibitor (TKI) dasatinib experience increase in WBC Count – due to lymphocytosis. And this is a good thing for them since it is associated with higher response rates and increased survival in patients.
This was confirmed in a study of 1402 patients led by Charles A. Schiffer, MD, of the Barbara Ann Karmanos Cancer Institute at Wayne State University in Detroit, USA.
Lymphocytosis developed in 32% to 35% of patients, and the condition persisted for at least 12 months in 52% to 77% of patients.
Lymphocytosis was associated with higher rates of complete cytogenetic response (CCyR) compared to those without lymphocytosis in all phases of CML, including newly diagnosed chronic-phase disease (P = .0166), imatinib-resistant/intolerant CML (P = .0011), accelerated-phase CML (P = .0004), and CML in myeloid blast phase (P = .0030). ?
Another interesting point is that patients with CML who are on dasatinib and develop pleural effusion, are also likely to have lymphocytosis.
?This is the value of personalised medicine and precision oncology that Asian Cancer Institute offers to its patients. For us each individual patient is unique and is given advise beyond the standard of care.